Case-mix adjustment to compare nationwide hospital performances after resection of colorectal liver metastases.


Journal

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
ISSN: 1532-2157
Titre abrégé: Eur J Surg Oncol
Pays: England
ID NLM: 8504356

Informations de publication

Date de publication:
03 2021
Historique:
received: 09 09 2020
revised: 07 10 2020
accepted: 12 10 2020
pubmed: 14 11 2020
medline: 15 9 2021
entrez: 13 11 2020
Statut: ppublish

Résumé

Differences in patient demographics and disease burden can influence comparison of hospital performances. This study aimed to provide a case-mix model to compare short-term postoperative outcomes for patients undergoing liver resection for colorectal liver metastases (CRLM). This retrospective, population-based study included all patients who underwent liver resection for CRLM between 2014 and 2018 in the Netherlands. Variation in case-mix variables between hospitals and influence on postoperative outcomes was assessed using multivariable logistic regression. Primary outcomes were 30-day major morbidity and 30-day mortality. Validation of results was performed on the data from 2019. In total, 4639 patients were included in 28 hospitals. Major morbidity was 6.2% and mortality was 1.4%. Uncorrected major morbidity ranged from 3.3% to 13.7% and mortality ranged from 0.0% to 5.0%. between hospitals. Significant differences between hospitals were observed for age higher than 80 (0.0%-17.1%, p < 0.001), ASA 3 or higher (3.3%-36.3%, p < 0.001), histopathological parenchymal liver disease (0.0%-47.1%, p < 0.001), history of liver resection (8.1%-36.3%, p < 0.001), major liver resection (6.7%-38.0%, p < 0.001) and synchronous metastases (35.5%-62.1%, p < 0.001). Expected 30-day major morbidity between hospitals ranged from 6.4% to 11.9% and expected 30-day mortality ranged from 0.6% to 2.9%. After case-mix correction no significant outliers concerning major morbidity and mortality remained. Validation on patients who underwent liver resection for CRLM in 2019 affirmed these outcomes. Case-mix adjustment is a prerequisite to allow for institutional comparison of short-term postoperative outcomes after liver resection for CRLM.

Sections du résumé

BACKGROUND
Differences in patient demographics and disease burden can influence comparison of hospital performances. This study aimed to provide a case-mix model to compare short-term postoperative outcomes for patients undergoing liver resection for colorectal liver metastases (CRLM).
METHODS
This retrospective, population-based study included all patients who underwent liver resection for CRLM between 2014 and 2018 in the Netherlands. Variation in case-mix variables between hospitals and influence on postoperative outcomes was assessed using multivariable logistic regression. Primary outcomes were 30-day major morbidity and 30-day mortality. Validation of results was performed on the data from 2019.
RESULTS
In total, 4639 patients were included in 28 hospitals. Major morbidity was 6.2% and mortality was 1.4%. Uncorrected major morbidity ranged from 3.3% to 13.7% and mortality ranged from 0.0% to 5.0%. between hospitals. Significant differences between hospitals were observed for age higher than 80 (0.0%-17.1%, p < 0.001), ASA 3 or higher (3.3%-36.3%, p < 0.001), histopathological parenchymal liver disease (0.0%-47.1%, p < 0.001), history of liver resection (8.1%-36.3%, p < 0.001), major liver resection (6.7%-38.0%, p < 0.001) and synchronous metastases (35.5%-62.1%, p < 0.001). Expected 30-day major morbidity between hospitals ranged from 6.4% to 11.9% and expected 30-day mortality ranged from 0.6% to 2.9%. After case-mix correction no significant outliers concerning major morbidity and mortality remained. Validation on patients who underwent liver resection for CRLM in 2019 affirmed these outcomes.
CONCLUSION
Case-mix adjustment is a prerequisite to allow for institutional comparison of short-term postoperative outcomes after liver resection for CRLM.

Identifiants

pubmed: 33183927
pii: S0748-7983(20)30848-9
doi: 10.1016/j.ejso.2020.10.016
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

649-659

Investigateurs

Marc G H Besselink (MGH)
Marieke T de Boer (MT)
Cees H C Dejong (CHC)
Thomas M van Gulik (TM)
Jeroen Hagendoorn (J)
Frederik H J Hoogwater (FHJ)
I Quintus Molenaar (IQ)
Mike S L Liem (MSL)

Informations de copyright

Copyright © 2020 University Medical Center Groningen. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of conpeting interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Arthur K E Elfrink (AKE)

Dutch Institute for Clinical Auditing, Scientific Bureau, Leiden, the Netherlands; Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands. Electronic address: a.elfrink@dica.nl.

Erik W van Zwet (EW)

Department of Biomedical Data Sciences, LUMC, Leiden, the Netherlands.

Rutger-Jan Swijnenburg (RJ)

Department of Surgery, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, the Netherlands.

Marcel den Dulk (M)

Department of Surgery, Maastricht University Medical Center, Maastricht, the Netherlands.

Peter B van den Boezem (PB)

Department of Surgery, Radboud Medical Center, Nijmegen, the Netherlands.

J Sven D Mieog (JSD)

Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.

Wouter W Te Riele (WW)

Department of Surgery, University Medical Center Utrecht, Utrecht, the Netherlands; Department of Surgery, St. Antonius Hospital, Nieuwegein, the Netherlands.

Gijs A Patijn (GA)

Department of Surgery, Isala, Zwolle, the Netherlands.

Wouter K G Leclercq (WKG)

Department of Surgery, Máxima Medical Center, Veldhoven, the Netherlands.

Daan J Lips (DJ)

Department of Surgery, Medisch Spectrum Twente, Enschede, the Netherlands.

Arjen M Rijken (AM)

Department of Surgery, Amphia Hospital, Breda, the Netherlands.

Cornelis Verhoef (C)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Koert F D Kuhlmann (KFD)

Department of Surgery, Antoni van Leeuwenhoek - Dutch Cancer Institute, Amsterdam, the Netherlands.

Carlijn I Buis (CI)

Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.

Koop Bosscha (K)

Department of Surgery, Jeroen Bosch Ziekenhuis, 's Hertogenbosch, the Netherlands.

Eric J T Belt (EJT)

Department of Surgery, Albert Schweitzer Hospital, Dordrecht, the Netherlands.

Maarten Vermaas (M)

Department of Surgery, Ijsselland Hospital, Capelle a/d Ijssel, the Netherlands.

N Tjarda van Heek (NT)

Department of Surgery, Gelderse Vallei, Ede, the Netherlands.

Steven J Oosterling (SJ)

Department of Surgery, Spaarne Gasthuis, Hoofddorp, the Netherlands.

Hans Torrenga (H)

Department of Surgery, Deventer Hospital, Deventer, the Netherlands.

Hasan H Eker (HH)

Department of Surgery, Medical Centre Leeuwarden, Leeuwarden, the Netherlands.

Esther C J Consten (ECJ)

Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands; Department of Surgery, Meander Medical Centre, Amersfoort, the Netherlands.

Hendrik A Marsman (HA)

Department of Surgery, OLVG, Amsterdam, the Netherlands.

Michel W J M Wouters (MWJM)

Dutch Institute for Clinical Auditing, Scientific Bureau, Leiden, the Netherlands.

Niels F M Kok (NFM)

Department of Surgery, Antoni van Leeuwenhoek - Dutch Cancer Institute, Amsterdam, the Netherlands.

Dirk J Grünhagen (DJ)

Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.

Joost M Klaase (JM)

Department of Surgery, University Medical Center Groningen, Groningen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH